Preclinical assessments of vaginal microbicide candidate safety and efficacy.

[1]  A. Gettie,et al.  A MIV-150/Zinc Acetate Gel Inhibits SHIV-RT Infection in Macaque Vaginal Explants , 2014, PloS one.

[2]  B. Herold,et al.  In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition. , 2014, Antiviral research.

[3]  K. Woodrow,et al.  Electrospun Solid Dispersions of Maraviroc for Rapid Intravaginal Preexposure Prophylaxis of HIV , 2014, Antimicrobial Agents and Chemotherapy.

[4]  M. Remacle,et al.  Use of cidofovir in HPV patients with recurrent respiratory papillomatosis , 2014, European Archives of Oto-Rhino-Laryngology.

[5]  A. Gettie,et al.  A Potent Combination Microbicide that Targets SHIV-RT, HSV-2 and HPV , 2014, PloS one.

[6]  W. Heneine,et al.  Postexposure Protection of Macaques from Vaginal SHIV Infection by Topical Integrase Inhibitors , 2014, Science Translational Medicine.

[7]  A. Gettie,et al.  MIV-150-Containing Intravaginal Rings Protect Macaque Vaginal Explants against SHIV-RT Infection , 2014, Antimicrobial Agents and Chemotherapy.

[8]  N. Shelke,et al.  Engineering a Segmented Dual-Reservoir Polyurethane Intravaginal Ring for Simultaneous Prevention of HIV Transmission and Unwanted Pregnancy , 2014, PloS one.

[9]  A. Gettie,et al.  Exposure to MIV-150 from a High-Dose Intravaginal Ring Results in Limited Emergence of Drug Resistance Mutations in SHIV-RT Infected Rhesus Macaques , 2014, PloS one.

[10]  G. Doncel,et al.  Pharmacokinetic and Safety Analyses of Tenofovir and Tenofovir-Emtricitabine Vaginal Tablets in Pigtailed Macaques , 2014, Antimicrobial Agents and Chemotherapy.

[11]  G. Doncel,et al.  Herpes simplex virus type-2 stimulates HIV-1 replication in cervical tissues: implications for HIV-1 transmission and efficacy of anti-HIV-1 microbicides , 2014, Mucosal Immunology.

[12]  A. Gettie,et al.  A combination microbicide gel protects macaques against vaginal simian human immunodeficiency virus-reverse transcriptase infection, but only partially reduces herpes simplex virus-2 infection after a single high-dose cochallenge. , 2014, AIDS research and human retroviruses.

[13]  B. Herold,et al.  Vaginally Delivered Tenofovir Disoproxil Fumarate Provides Greater Protection than Tenofovir against Genital Herpes in a Murine Model of Efficacy and Safety , 2013, Antimicrobial Agents and Chemotherapy.

[14]  J. Romano,et al.  Prioritizing multipurpose prevention technology development and investments using a target product profile. , 2013, Antiviral research.

[15]  C. Woodsong,et al.  Development of dapivirine vaginal ring for HIV prevention. , 2013, Antiviral research.

[16]  K. Whaley,et al.  Antibody-based concepts for multipurpose prevention technologies. , 2013, Antiviral research.

[17]  A. Gettie,et al.  The Frequency of &agr;4&bgr;7high Memory CD4+ T Cells Correlates With Susceptibility to Rectal Simian Immunodeficiency Virus Infection , 2013, Journal of acquired immune deficiency syndromes.

[18]  R. Buckheit,et al.  Selection and characterization of viruses resistant to the dual acting pyrimidinedione entry and non-nucleoside reverse transcriptase inhibitor IQP-0410. , 2013, Antiviral research.

[19]  B. Herold,et al.  Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties , 2013, Retrovirology.

[20]  J. Cummins,et al.  Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention. , 2013, AIDS research and human retroviruses.

[21]  B. Herold,et al.  Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges , 2013, Proceedings of the National Academy of Sciences.

[22]  D. Volsky,et al.  Transmission of chimeric HIV by mating in conventional mice: prevention by pre-exposure antiretroviral therapy and reduced susceptibility during estrus , 2013, Disease Models & Mechanisms.

[23]  C. Meyers,et al.  Differential Dependence on Host Cell Glycosaminoglycans for Infection of Epithelial Cells by High-Risk HPV Types , 2013, PloS one.

[24]  A. Gettie,et al.  A Modified Zinc Acetate Gel, a Potential Nonantiretroviral Microbicide, Is Safe and Effective against Simian-Human Immunodeficiency Virus and Herpes Simplex Virus 2 Infection In Vivo , 2013, Antimicrobial Agents and Chemotherapy.

[25]  W. Heneine,et al.  Lack of Prophylactic Efficacy of Oral Maraviroc in Macaques despite High Drug Concentrations in Rectal Tissues , 2013, Journal of Virology.

[26]  D. Friend,et al.  Development and characterisation of a self-microemulsifying drug delivery systems (SMEDDSs) for the vaginal administration of the antiretroviral UC-781. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[27]  M. Stefanidou,et al.  Griffithsin Protects Mice from Genital Herpes by Preventing Cell-to-Cell Spread , 2013, Journal of Virology.

[28]  C. Dezzutti,et al.  Use of Human Mucosal Tissue to Study HIV-1 Pathogenesis and Evaluate HIV-1 Prevention Modalities , 2013, Current HIV/AIDS Reports.

[29]  W. Heneine,et al.  Prevention of Vaginal SHIV Transmission in Macaques by a Coitally-Dependent Truvada Regimen , 2012, PloS one.

[30]  P. Pennings.  HIV Drug Resistance: Problems and Perspectives , 2012, Infectious disease reports.

[31]  S. Garland,et al.  A review of clinical trials of human papillomavirus prophylactic vaccines. , 2012, Vaccine.

[32]  R. Hayes,et al.  Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis , 2012, AIDS.

[33]  D. Friend,et al.  Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits. , 2012, AIDS research and human retroviruses.

[34]  A. Gettie,et al.  A single dose of a MIV-150/Zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use. , 2012, AIDS research and human retroviruses.

[35]  A. Gettie,et al.  The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection. , 2012, AIDS research and human retroviruses.

[36]  G. Doncel,et al.  A 90-Day Tenofovir Reservoir Intravaginal Ring for Mucosal HIV Prophylaxis , 2012, Antimicrobial Agents and Chemotherapy.

[37]  R. Maserati,et al.  Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation , 2012, Expert opinion on drug metabolism & toxicology.

[38]  A. Gettie,et al.  An Intravaginal Ring That Releases the NNRTI MIV-150 Reduces SHIV Transmission in Macaques , 2012, Science Translational Medicine.

[39]  C. Dezzutti,et al.  Reformulated tenofovir gel for use as a dual compartment microbicide. , 2012, The Journal of antimicrobial chemotherapy.

[40]  Z. Rosenberg,et al.  Future strategies in microbicide development. , 2012, Best practice & research. Clinical obstetrics & gynaecology.

[41]  B. Herold,et al.  Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. , 2012, The Journal of antimicrobial chemotherapy.

[42]  J. Garcia,et al.  Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. , 2012, Trends in microbiology.

[43]  C. Dezzutti,et al.  Characterization of UC781-Tenofovir Combination Gel Products for HIV-1 Infection Prevention in an Ex Vivo Ectocervical Model , 2012, Antimicrobial Agents and Chemotherapy.

[44]  L. Rohan,et al.  Testing of viscous anti-HIV microbicides using Lactobacillus. , 2012, Journal of microbiological methods.

[45]  D. Lowy,et al.  Reducing HPV-Associated Cancer Globally , 2012, Cancer Prevention Research.

[46]  M. Wainberg,et al.  In Vitro Resistance Profile of the Candidate HIV-1 Microbicide Drug Dapivirine , 2011, Antimicrobial Agents and Chemotherapy.

[47]  D. Richman,et al.  Associations between Virologic and Immunologic Dynamics in Blood and in the Male Genital Tract , 2011, Journal of Virology.

[48]  G. Doncel,et al.  Bridging the Gap between Preclinical and Clinical Microbicide Trials: Blind Evaluation of Candidate Gels in Murine Models of Efficacy and Safety , 2011, PloS one.

[49]  W. Heneine,et al.  Durable Protection from Vaginal Simian-Human Immunodeficiency Virus Infection in Macaques by Tenofovir Gel and Its Relationship to Drug Levels in Tissue , 2011, Journal of Virology.

[50]  J. Peters,et al.  Zinc Acetate/Carrageenan Gels Exhibit Potent Activity In Vivo against High-Dose Herpes Simplex Virus 2 Vaginal and Rectal Challenge , 2011, Antimicrobial Agents and Chemotherapy.

[51]  Joseph P. Romano,et al.  Pharmacokinetics of Tenofovir following Intravaginal and Intrarectal Administration of Tenofovir Gel to Rhesus Macaques , 2011, Antimicrobial Agents and Chemotherapy.

[52]  E. Martinelli,et al.  Myeloid dendritic cells in HIV-1 infection. , 2011, Current opinion in HIV and AIDS.

[53]  David Katz,et al.  Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro. , 2011, AIDS research and human retroviruses.

[54]  N. Matoba,et al.  Investigation of Griffithsin's Interactions with Human Cells Confirms Its Outstanding Safety and Efficacy Profile as a Microbicide Candidate , 2011, PloS one.

[55]  W. Heneine,et al.  High Susceptibility to Repeated, Low-Dose, Vaginal SHIV Exposure Late in the Luteal Phase of the Menstrual Cycle of Pigtail Macaques , 2011, Journal of acquired immune deficiency syndromes.

[56]  Brigitte E. Sanders-Beer,et al.  Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus , 2011, Mucosal Immunology.

[57]  A. Gettie,et al.  HSV-2 Infection of Dendritic Cells Amplifies a Highly Susceptible HIV-1 Cell Target , 2011, PLoS pathogens.

[58]  E. Appella,et al.  One Percent Tenofovir Applied Topically to Humanized BLT Mice and Used According to the CAPRISA 004 Experimental Design Demonstrates Partial Protection from Vaginal HIV Infection, Validating the BLT Model for Evaluation of New Microbicide Candidates , 2011, Journal of Virology.

[59]  D. Lowy,et al.  Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. , 2011, Journal of the National Cancer Institute.

[60]  A. Wald,et al.  Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. , 2011, JAMA.

[61]  A. Gettie,et al.  An Antiretroviral/Zinc Combination Gel Provides 24 Hours of Complete Protection against Vaginal SHIV Infection in Macaques , 2011, PloS one.

[62]  G. Doncel,et al.  Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers. , 2010, Antiviral research.

[63]  R. Mumper,et al.  Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse , 2010, BMC infectious diseases.

[64]  Sepideh Habibi,et al.  Pharmacokinetics of 2 Dapivirine Vaginal Microbicide Gels and Their Safety Vs. Hydroxyethyl Cellulose-Based Universal Placebo Gel , 2010, Journal of acquired immune deficiency syndromes.

[65]  Lynn Morris,et al.  Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.

[66]  Yunda Huang,et al.  In Vitro and Ex Vivo Testing of Tenofovir Shows It Is Effective As an HIV-1 Microbicide , 2010, PloS one.

[67]  V. Piguet,et al.  Vaccines and microbicides preventing HIV-1, HSV-2, and HPV mucosal transmission. , 2010, The Journal of investigative dermatology.

[68]  D. Schust,et al.  Caveats associated with the use of human cervical tissue for HIV and microbicide research. , 2010, AIDS.

[69]  R. Kaul,et al.  The integrin α4β7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1 , 2009, Proceedings of the National Academy of Sciences.

[70]  A. Gettie,et al.  A Macaque Model to Study Vaginal HSV-2/Immunodeficiency Virus Co-Infection and the Impact of HSV-2 on Microbicide Efficacy , 2009, PloS one.

[71]  Sarah S. Wilson,et al.  Susceptibility to Genital Herpes as a Biomarker Predictive of Increased HIV Risk: Expansion of a Murine Model of Microbicide Safety , 2009, Antiviral therapy.

[72]  W. Heneine,et al.  Complete Protection from Repeated Vaginal Simian-Human Immunodeficiency Virus Exposures in Macaques by a Topical Gel Containing Tenofovir Alone or with Emtricitabine , 2009, Journal of Virology.

[73]  Sarah S. Wilson,et al.  Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. , 2009, The Journal of infectious diseases.

[74]  S. Kapiga,et al.  Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women , 2009, AIDS.

[75]  L. V. Van Bortel,et al.  Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. , 2009, AIDS research and human retroviruses.

[76]  Massoud Motamedi,et al.  High Resolution Imaging of Epithelial Injury in the Sheep Cervicovaginal Tract: A Promising Model for Testing Safety of Candidate Microbicides , 2009, Sexually transmitted diseases.

[77]  David C. Montefiori,et al.  Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component , 2009, Proceedings of the National Academy of Sciences.

[78]  J. Grivel,et al.  Use of human tissue explants to study human infectious agents , 2009, Nature Protocols.

[79]  R. Shattock,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Infection by the Candidate Microbicide Dapivirine, a Nonnucleoside Reverse Transcriptase Inhibitor , 2008, Antimicrobial Agents and Chemotherapy.

[80]  A. Wald,et al.  Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. , 2008, The Journal of infectious diseases.

[81]  Brigitte E. Sanders-Beer,et al.  Development of a Comprehensive Human Immunodeficiency Virus Type 1 Screening Algorithm for Discovery and Preclinical Testing of Topical Microbicides , 2008, Antimicrobial Agents and Chemotherapy.

[82]  J. Nuttall,et al.  Concentrations of Dapivirine in the Rhesus Macaque and Rabbit following Once Daily Intravaginal Administration of a Gel Formulation of [14C]Dapivirine for 7 Days , 2007, Antimicrobial Agents and Chemotherapy.

[83]  B. Galen,et al.  Seminal plasma reduces the effectiveness of topical polyanionic microbicides. , 2007, The Journal of infectious diseases.

[84]  P. Choyke,et al.  Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan , 2007, Nature Medicine.

[85]  R. Shattock,et al.  Molecular Umbrellas: a Novel Class of Candidate Topical Microbicides To Prevent Human Immunodeficiency Virus and Herpes Simplex Virus Infections , 2007, Journal of Virology.

[86]  L. Grohskopf,et al.  Preclinical Testing of Candidate Topical Microbicides for Anti-Human Immunodeficiency Virus Type 1 Activity and Tissue Toxicity in a Human Cervical Explant Culture , 2007, Antimicrobial Agents and Chemotherapy.

[87]  L. Corey.  Herpes simplex virus type 2 and HIV-1: the dialogue between the 2 organisms continues. , 2007, The Journal of infectious diseases.

[88]  M. McElrath,et al.  Initial Events in Establishing Vaginal Entry and Infection by Human Immunodeficiency Virus Type-1 , 2007, Immunity.

[89]  D. Phillips,et al.  Carrageenan/MIV-150 (PC-815), a Combination Microbicide , 2007, Sexually transmitted diseases.

[90]  S. Hillier,et al.  Vaginal and Rectal Topical Microbicide Development: Safety and Efficacy of 1.0% Savvy (C31G) in the Pigtailed Macaque , 2006, Sexually transmitted diseases.

[91]  P. Gallay,et al.  Cell-Free Human Immunodeficiency Virus Type 1 Transcytosis through Primary Genital Epithelial Cells , 2006, Journal of Virology.

[92]  Robert A. Anderson,et al.  ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: optimal candidate for microbicide combinations. , 2006, The Journal of infectious diseases.

[93]  D. Lowy,et al.  Carrageenan Is a Potent Inhibitor of Papillomavirus Infection , 2006, PLoS pathogens.

[94]  S. Hillier,et al.  Preclinical Safety and Efficacy Assessments of Dendrimer-Based (SPL7013) Microbicide Gel Formulations in a Nonhuman Primate Model , 2006, Antimicrobial Agents and Chemotherapy.

[95]  G. Prince,et al.  The Cotton Rat Provides a Novel Model To Study Genital Herpes Infection and To Evaluate Preventive Strategies , 2005, Journal of Virology.

[96]  John P. Moore,et al.  Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor , 2005, Nature Medicine.

[97]  John P. Moore,et al.  Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus–cell fusion , 2005, Nature.

[98]  L. Margolis,et al.  The Nonnucleoside Reverse Transcriptase Inhibitor UC-781 Inhibits Human Immunodeficiency Virus Type 1 Infection of Human Cervical Tissue and Dissemination by Migratory Cells , 2005, Journal of Virology.

[99]  Barry R O'Keefe,et al.  Isolation and Characterization of Griffithsin, a Novel HIV-inactivating Protein, from the Red Alga Griffithsia sp.* , 2005, Journal of Biological Chemistry.

[100]  G. Doncel,et al.  Preclinical assessment of the proinflammatory potential of microbicide candidates , 2004, Journal of acquired immune deficiency syndromes.

[101]  K. Gustafson,et al.  Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. , 2004, AIDS research and human retroviruses.

[102]  F. Krebs,et al.  Mouse Model of Cervicovaginal Toxicity and Inflammation for Preclinical Evaluation of Topical Vaginal Microbicides , 2004, Antimicrobial Agents and Chemotherapy.

[103]  John P. Moore,et al.  Blockade of Attachment and Fusion Receptors Inhibits HIV-1 Infection of Human Cervical Tissue , 2004, The Journal of experimental medicine.

[104]  S. Hillier,et al.  Macaca fascicularis vs. Macaca nemestrina as a model for topical microbicide safety studies , 2004, Journal of medical primatology.

[105]  S. Philpott.  HIV-1 coreceptor usage, transmission, and disease progression. , 2003, Current HIV research.

[106]  John P. Moore,et al.  Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120 , 2003, Nature Medicine.

[107]  Simon C Watkins,et al.  Memory CD4+ T Cells Are the Earliest Detectable Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Cells in the Female Genital Mucosal Tissue during HIV-1 Transmission in an Organ Culture System , 2002, Journal of Virology.

[108]  Naomi Bergman,et al.  Comparison of Microbicides for Efficacy in Protecting Mice Against Vaginal Challenge With Herpes Simplex Virus Type 2, Cytotoxicity, Antibacterial Properties, and Sperm Immobilization , 2001, Sexually transmitted diseases.

[109]  P. Watts,et al.  Parameters of Human Immunodeficiency Virus Infection of Human Cervical Tissue and Inhibition by Vaginal Virucides , 2000, Journal of Virology.

[110]  Phalguni Gupta,et al.  Development of an in vitro organ culture model to study transmission of HIV-1 in the female genital tract , 2000, Nature Medicine.

[111]  D. Phillips,et al.  Carrageenan‐Based Nonoxynol‐9 Spermicides for Prevention of Sexually Transmitted Infections , 1998, Sexually transmitted diseases.

[112]  B. Roizman,et al.  Herpes simplex viruses: is a vaccine tenable? , 2002, The Journal of clinical investigation.

[113]  M. Ozbun,et al.  Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA , 1997, Journal of virology.

[114]  S. Inglis,et al.  A Genetically Inactivated Herpes Simplex Virus Type 2 (HSV-2) Vaccine Provides Effective Protection against Primary and Recurrent HSV-2 Disease , 1997, The Journal of infectious diseases.

[115]  C. Meyers,et al.  Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. , 1992, Science.

[116]  Barbara F. Matthies,et al.  The American Heritage dictionary of the English language , 1969 .

[117]  M. C. Jackson,et al.  Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys. , 1969, Journal of reproduction and fertility.

[118]  D. Colagiovanni,et al.  Preparation of a Preclinical Dossier to Support an Investigational New Drug (IND) Application and First-In-Human Clinical Trial , 2013 .

[119]  G. Doncel,et al.  Non-specific microbicide product development: then and now. , 2012, Current HIV research.

[120]  C..  Antivirals for Cytomegalovirus Infection in Neonates and Infants Focus on Pharmacokinetics , Formulations , Dosing , and Adverse Events , 2011 .

[121]  R. Shattock,et al.  Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. , 2009, The Journal of general virology.

[122]  S. Turville,et al.  Resolution of de novo HIV production and trafficking in immature dendritic cells , 2008, Nature Methods.

[123]  S. Wallenstein,et al.  PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. , 2006, The Journal of infectious diseases.

[124]  E. Petersen,et al.  Herpes simplex viruses. , 2009 .